Sugi Predict

Sugi Predict / Compounds / SCHEMBL188329

SCHEMBL188329

SCHEMBL188329

CC(C)=CCC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.74

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.74
▸ MEN1 O00255 2/20 0.74
▸ KMT2A Q03164 2/20 0.74
▸ USP2 O75604 1/20 0.74
▸ MAPT P10636 1/20 0.74
▸ ALOX15 P16050 1/20 0.74
▸ DHCR24 Q15392 11/20 0.74
▸ TRPV1 Q8NER1 1/20 0.61
▸ RORC P51449 2/20 0.61
▸ THRB P10828 1/20 0.50
▸ CYP3A4 P08684 1/20 0.42
▸ NR1I2 O75469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL847506 1.00 ALDH1A1 (0.74) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL24300840 1.00 ALDH1A1 (0.74) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL335520 1.00 ALDH1A1 (0.74) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL335521 1.00 ALDH1A1 (0.74) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL30650209 0.93 ALDH1A1 (0.71) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL9155413 0.90 RORC (0.80) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL7624350 0.89 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL15123702 0.89 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL14911153 0.87 ALDH1A1 (0.80) ALDH1A1MEN1KMT2AUSP2MAPT
SCHEMBL1237838 0.85 ALDH1A1 (0.77) ALDH1A1MEN1KMT2AUSP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047961-A1 THE CHOLESTEROL-SYNTESIS INTERMEDIATES FOR TREATMENT DEMYELINATING DISORDERS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-02-16 — — US claimed
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
US-20240050587-A1 LIPOSOMES COMPRISING ANTI-LOX ANTIBODY ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI "DINO AMADORI" - IRST S.R.L. (IT) 2024-02-15 — — US disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 — — WO disclosed
US-20230047961-A1 THE CHOLESTEROL-SYNTESIS INTERMEDIATES FOR TREATMENT DEMYELINATING DISORDERS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-02-16 — — US disclosed
WO-2021064076-A1 LIPOSOMES COMPRISING ANTI-LOX ANTIBODY ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (I.R.S.T.) S.R.L. (IT) 2021-04-08 — — WO disclosed
US-10000770-B2 Methods of expressing products in mammalian cells INTREXON CEU, INC. (US) 2018-06-19 — — US disclosed
EP-2401696-B1 MAMMALIAN CELL LINE MODELS AND RELATED METHODS INTREXON CEU INC (US) 2017-06-21 — — EP disclosed
US-9673030-B2 Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry EMORY UNIVERSITY (US) 2017-06-06 — — US disclosed
WO-2012027533-A1 SELECTABLE MARKERS AND RELATED METHODS GT LIFE SCIENCES, INC. (US) 2012-03-01 — — WO disclosed
EP-2401696-A1 MAMMALIAN CELL LINE MODELS AND RELATED METHODS GT Life Sciences, Inc. (US) 2012-01-04 — — EP disclosed
US-20110282587-A1 COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY EMORY UNIVERSITY (US) 2011-11-17 — — US disclosed
US-20110246081-A1 Metabolomics-Based Identification of Disease-Causing Agents GEORGIA TECH RESEARCH CORPORATION (US) 2011-10-06 — — US disclosed
WO-2010098865-A1 MAMMALIAN CELL LINE MODELS AND RELATED METHODS GT LIFE SCIENCES, INC. (US) 2010-09-02 — — WO disclosed
WO-2009052186-A1 METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2009-04-23 — — WO disclosed
EP-0636139-B1 ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE STANFORD RES INST INT (US) 1999-11-17 — — EP disclosed
US-5391777-A Isolation of steroids containing a 5,7-diene functionality from a sterol mixture SRI INTERNATIONAL (US) 1995-02-21 — — US disclosed
EP-0636139-A1 ISOLATION OF STEROIDS CONTAINING A 5,7-DIENE FUNCTIONALITY FROM A STEROL MIXTURE SRI INTERNATIONAL (US) 1995-02-01 — — EP disclosed
WO-1993021204-A1 METHOD FOR PREPARING CHOLESTA-5,7-DIENE-3-BETA,25-DIOL AND ANALOGS THEREOF SRI INTERNATIONAL (US) 1993-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319190-A1 APOE LIPOPROTEIN SYSTEMS APOB, APOL1, LDLR ALDH1A1 3260/4885MEN1 3385/4885KMT2A 4008/4885
US-20230047961-A1 THE CHOLESTEROL-SYNTESIS INTERMEDIATES FOR TREATMENT DEMYELINATING DISORDERS HMGCR, SGMS1, CETP ALDH1A1 4421/4885MEN1 607/4885KMT2A 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.